Literature DB >> 20495640

Incidence and characteristics of chronic and lymphoplasmacytic sclerosing pancreatitis in patients scheduled to undergo a pancreatoduodenectomy.

Steve M M de Castro1, Lindsey C F de Nes, C Yung Nio, Daan C Velseboer, Fiebo J W ten Kate, Olivier R C Busch, Thomas M van Gulik, Dirk Jan Gouma.   

Abstract

BACKGROUND: The determination of the exact nature of a pancreatic head mass in a patient scheduled to undergo a pancreatoduodenectomy can be very difficult. This is important as patients who suffer from benign disease such as pancreatitis do not always require surgery. The aim of the present study was to analyse the incidence of pancreatitis and the signs and symptoms associated with these tumours mistaken for pancreatic cancer and the diagnostic procedures performed.
METHODS: A consecutive group of patients who underwent a pancreatoduodenectomy between 1992 and 2005 with histopathologically proven pancreatic adenocarcinoma (PCA) and pancreatitis were analysed.
RESULTS: The incidence of pancreatitis after pancreatoduodenectomy is 63 out of 639 patients who underwent a pancreaticoduodenectomy (9.9%). Of these patients, 24 patients (38%) had lymphoplasmacytic sclerosing pancreatitis (LPSP) and 31 patients (49%) had focal chronic pancreatitis. Eight patients (13%) had an intermediate form with characteristics of both. Pancreatic adenocarcinoma occurred in 227 patients (36%). The presence of pancreatitis without a discrete mass on endoscopic ultrasonography (EUS) seemed to have clinical relevance with a positive likelihood ratio of 5.1. Mortality after resection was nil in both groups.
CONCLUSION: The incidence of pancreatitis is 9.9% for patients scheduled to undergo a pancreatoduodenectomy. Of these patients, 38% had LPSP, 13% had a intermediate form and 49% had focal chronic pancreatitis. The determination of the exact nature of a pancreatic head mass remains difficult.

Entities:  

Mesh:

Year:  2010        PMID: 20495640      PMCID: PMC2814399          DOI: 10.1111/j.1477-2574.2009.00112.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  37 in total

Review 1.  [Diagnostics and treatment of distal bile duct or pancreatic carcinoma; guidelines of the Amsterdam and Twente Comprehensive Cancer Centers].

Authors:  D J Gouma; E H Tilleman; J Benraadt; P M Bossuyt
Journal:  Ned Tijdschr Geneeskd       Date:  2001-07-14

2.  IgG4 levels in non-Japanese patients with autoimmune sclerosing pancreatitis.

Authors:  Robert Y M Chen; David B Adams
Journal:  N Engl J Med       Date:  2002-06-13       Impact factor: 91.245

Review 3.  Hospital volume and mortality after pancreatic resection: a systematic review and an evaluation of intervention in the Netherlands.

Authors:  N Tjarda van Heek; Koert F D Kuhlmann; Rob J Scholten; Steve M M de Castro; Olivier R C Busch; Thomas M van Gulik; Huug Obertop; Dirk J Gouma
Journal:  Ann Surg       Date:  2005-12       Impact factor: 12.969

4.  Autoimmune pancreatitis detected as a mass in the tail of the pancreas.

Authors:  T Taniguchi; S Seko; K Azuma; M Tamegai; O Nishida; F Inoue; M Okamoto; T Mizumoto; H Kobayashi
Journal:  J Gastroenterol Hepatol       Date:  2000-04       Impact factor: 4.029

5.  High serum IgG4 concentrations in patients with sclerosing pancreatitis.

Authors:  H Hamano; S Kawa; A Horiuchi; H Unno; N Furuya; T Akamatsu; M Fukushima; T Nikaido; K Nakayama; N Usuda; K Kiyosawa
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

6.  [Diagnosis and treatment of pancreatic carcinoma in the region of Amsterdam Comprehensive Cancer Care Center in 1997].

Authors:  E H Tilleman; J Benraadt; P M Bossuyt; H Obertop; D J Gouma
Journal:  Ned Tijdschr Geneeskd       Date:  2001-07-14

7.  Eosinophilic pancreatitis and increased eosinophils in the pancreas.

Authors:  Susan C Abraham; Steven Leach; Charles J Yeo; John L Cameron; Linda A Murakata; John K Boitnott; Jorge Albores-Saavedra; Ralph H Hruban
Journal:  Am J Surg Pathol       Date:  2003-03       Impact factor: 6.394

Review 8.  A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice.

Authors:  Miguel E Sewnath; Thomas M Karsten; Martin H Prins; Erik J A Rauws; Huug Obertop; Dirk J Gouma
Journal:  Ann Surg       Date:  2002-07       Impact factor: 12.969

9.  Lymphoplasmacytic sclerosing pancreatitis: inflammatory mimic of pancreatic carcinoma.

Authors:  Sharon M Weber; Olcay Cubukcu-Dimopulo; J Alexander Palesty; Arief Suriawinata; David Klimstra; Murray F Brennan; Kevin Conlon
Journal:  J Gastrointest Surg       Date:  2003-01       Impact factor: 3.452

10.  Pancreaticoduodenectomy (Whipple resections) in patients without malignancy: are they all 'chronic pancreatitis'?

Authors:  Susan C Abraham; Robb E Wilentz; Charles J Yeo; Taylor A Sohn; John L Cameron; John K Boitnott; Ralph H Hruban
Journal:  Am J Surg Pathol       Date:  2003-01       Impact factor: 6.394

View more
  13 in total

1.  Autoimmune pancreatitis characterized by predominant CD8+ T lymphocyte infiltration.

Authors:  She-Yu Li; Xiang-Yang Huang; Yong-Tao Chen; Yi Liu; Sha Zhao
Journal:  World J Gastroenterol       Date:  2011-11-07       Impact factor: 5.742

2.  Diagnosing and managing pancreatic cancer.

Authors:  Matthew T Huggett; Stephen P Pereira
Journal:  Practitioner       Date:  2011 Jul-Aug

3.  Endoscopic ultrasound-guided fine needle aspiration in the differentiation of type 1 and type 2 autoimmune pancreatitis.

Authors:  Takuya Ishikawa; Akihiro Itoh; Hiroki Kawashima; Eizaburo Ohno; Hiroshi Matsubara; Yuya Itoh; Yosuke Nakamura; Takeshi Hiramatsu; Masanao Nakamura; Ryoji Miyahara; Naoki Ohmiya; Hidemi Goto; Yoshiki Hirooka
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

4.  Serum level of Ca 19-9 increases ability of IgG4 test to distinguish patients with autoimmune pancreatitis from those with pancreatic carcinoma.

Authors:  Marianne J van Heerde; J Buijs; B E Hansen; M de Waart; C H J van Eijck; G Kazemier; C J Pek; J W Poley; M J Bruno; E J Kuipers; H R van Buuren
Journal:  Dig Dis Sci       Date:  2014-01-03       Impact factor: 3.199

5.  Differentiating autoimmune pancreatitis from pancreatic adenocarcinoma using dual-phase computed tomography.

Authors:  Atif Zaheer; Vikesh K Singh; Venkata S Akshintala; Satomi Kawamoto; Salina D Tsai; Kenneth L Gage; Elliot K Fishman
Journal:  J Comput Assist Tomogr       Date:  2014 Jan-Feb       Impact factor: 1.826

6.  Unexpected benign histopathology after pancreatoduodenectomy for presumed malignancy: accepting the inevitable.

Authors:  Rachel M Gomes; Munita Bal; Shraddha Patkar; Mahesh Goel; Shailesh V Shrikhande
Journal:  Langenbecks Arch Surg       Date:  2016-01-26       Impact factor: 3.445

7.  Autoimmune pancreatitis: Imaging features.

Authors:  Yi Dong; Mirko D'Onofrio; Michael Hocke; Christian Jenssen; Andrej Potthoff; Nathan Atkinson; Andre Ignee; Christoph F Dietrich
Journal:  Endosc Ultrasound       Date:  2018 May-Jun       Impact factor: 5.628

8.  Prevalence of autoimmune pancreatitis and other benign disorders in pancreatoduodenectomy for presumed malignancy of the pancreatic head.

Authors:  M J van Heerde; K Biermann; P E Zondervan; G Kazemier; C H J van Eijck; C Pek; E J Kuipers; H R van Buuren
Journal:  Dig Dis Sci       Date:  2012-05-16       Impact factor: 3.199

9.  Differentiation of Focal-Type Autoimmune Pancreatitis From Pancreatic Ductal Adenocarcinoma Using Radiomics Based on Multiphasic Computed Tomography.

Authors:  Linning E; Yan Xu; Zhifeng Wu; Li Li; Na Zhang; Hao Yang; Lawrence H Schwartz; Lin Lu; Binsheng Zhao
Journal:  J Comput Assist Tomogr       Date:  2020 Jul/Aug       Impact factor: 2.081

10.  Distinct pathophysiological cytokine profiles for discrimination between autoimmune pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma.

Authors:  Sahar Ghassem-Zadeh; Matthias M Gaida; Szilard Szanyi; Hans Acha-Orbea; Jean-Louis Frossard; Ulf Hinz; Thilo Hackert; Oliver Strobel; Klaus Felix
Journal:  J Transl Med       Date:  2017-06-02       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.